- Home
- MQ vs DNLI Comparison
MQ vs DNLI Comparison
Compare MQ & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MQ
- DNLI
- Stock Information
- Founded
- MQ 2010
- DNLI 2013
- Country
- MQ United States
- DNLI United States
- Employees
- MQ N/A
- DNLI N/A
- Industry
- MQ Computer Software: Prepackaged Software
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MQ Technology
- DNLI Health Care
- Exchange
- MQ Nasdaq
- DNLI Nasdaq
- Market Cap
- MQ 1.9B
- DNLI 2.1B
- IPO Year
- MQ 2021
- DNLI 2017
- Fundamental
- Price
- MQ $6.52
- DNLI $13.96
- Analyst Decision
- MQ Hold
- DNLI Strong Buy
- Analyst Count
- MQ 13
- DNLI 15
- Target Price
- MQ $5.98
- DNLI $33.85
- AVG Volume (30 Days)
- MQ 5.2M
- DNLI 1.6M
- Earning Date
- MQ 08-06-2025
- DNLI 08-19-2025
- Dividend Yield
- MQ N/A
- DNLI N/A
- EPS Growth
- MQ N/A
- DNLI N/A
- EPS
- MQ N/A
- DNLI N/A
- Revenue
- MQ $553,223,000.00
- DNLI N/A
- Revenue This Year
- MQ $18.12
- DNLI N/A
- Revenue Next Year
- MQ $22.15
- DNLI $323.34
- P/E Ratio
- MQ N/A
- DNLI N/A
- Revenue Growth
- MQ 17.47
- DNLI N/A
- 52 Week Low
- MQ $3.37
- DNLI $10.57
- 52 Week High
- MQ $7.04
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- MQ 66.61
- DNLI 47.68
- Support Level
- MQ $5.50
- DNLI $13.25
- Resistance Level
- MQ $5.68
- DNLI $14.46
- Average True Range (ATR)
- MQ 0.19
- DNLI 0.64
- MACD
- MQ 0.07
- DNLI 0.03
- Stochastic Oscillator
- MQ 66.65
- DNLI 48.63
About MQ Marqeta Inc.
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.